Corona Remedies Shares Soar Nearly 40% on Dalal Street Debut

• Corona Remedies shares debuted on Dalal Street with a nearly 40% premium.
• The company's IPO was subscribed 137 times during the bidding period.
• Shares listed at ₹1,470, a 38.42% premium over the issue price of ₹1,062.
• Analysts recommend booking partial listing gains and holding for long-term opportunities.
• Corona Remedies, a fast-growing Indian pharmaceutical company, raised ₹655.37 crore through an Offer For Sale.

Why It Matters: Strong IPO debut signals robust investor confidence and growth potential in pharma.